News
-
-
-
PRESS RELEASE
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Heidelberg Pharma announces royalty financing agreement with HealthCare Royalty for up to USD 115 million. Agreement to purchase royalties from Telix Pharmaceuticals for Zircaix(TM) -
PRESS RELEASE
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Heidelberg Pharma announces royalty financing agreement with HealthCare Royalty for up to USD 115 million. Agreement involves royalties from worldwide sales of Telix Pharmaceuticals' ZircaixTM -
PRESS RELEASE
Q Battery Metals Pursuing Diamond Drilling Contractor for 2024 Exploration La Corne South and Mckenzie East Projects, Quebec
Q Battery Metals Corp. is in discussion with a Diamond Drilling Contractor for drilling on properties in 2024. Exploration at La Corne South identifies potential for lithium and VMS mineralization -
PRESS RELEASE
MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp -
PRESS RELEASE
Original-Research: Alzchem Group AG (von Sphene Capital GmbH): Buy
Alzchem Group AG erhält Buy-Einstufung und Kursziel von EUR 43,40 durch Sphene Capital GmbH nach profitabler Jahresbilanz. Erfolgreiche Quartalsergebnisse und Strategien sorgen für positives Wachstum. Vollständige Analyse zum Download verfügbar -
-
-